Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph not_applicable
2
50%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (33.3%)
N/A2 (66.7%)

Trials by Status

completed375%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
completednot_applicable

Primary Diagnosis Study for Validation of Hamamatsu NanoZoomer S360MD Digital Slide Scanner System

NCT03991468
terminatedphase_2

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

NCT01118351
completednot_applicable

Hysterectomy for Benign Gynaecological Conditions With or Without Tubectomy

NCT02281487
completed

Laser Spectroscopy of Breast Tissue Through a Needle Device

NCT00918788

Clinical Trials (4)

Showing 4 of 4 trials
NCT03991468Not Applicable

Primary Diagnosis Study for Validation of Hamamatsu NanoZoomer S360MD Digital Slide Scanner System

Completed
NCT01118351Phase 2

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Terminated
NCT02281487Not Applicable

Hysterectomy for Benign Gynaecological Conditions With or Without Tubectomy

Completed
NCT00918788

Laser Spectroscopy of Breast Tissue Through a Needle Device

Completed

All 4 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
4